ZL-2306(nirapairb) + Placebos
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-sensitive Relapsed Ovarian Cancer
Conditions
Platinum-sensitive Relapsed Ovarian Cancer
Trial Timeline
Jun 8, 2017 → Aug 24, 2024
NCT ID
NCT03705156About ZL-2306(nirapairb) + Placebos
ZL-2306(nirapairb) + Placebos is a phase 3 stage product being developed by Zai Lab for Platinum-sensitive Relapsed Ovarian Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT03705156. Target conditions include Platinum-sensitive Relapsed Ovarian Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03705156 | Phase 3 | UNKNOWN |
Competing Products
4 competing products in Platinum-sensitive Relapsed Ovarian Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Farletuzumab + Placebo | Eisai | Phase 2 | 52 |
| OSE2101 + Pembrolizumab 25 MG/ML [Keytruda] | Merck | Phase 2 | 52 |
| Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| AK112 low dose + Chemotherapy + Olaparib + AK112 high dose | Akeso | Phase 2 | 51 |